Synergistic chemo-immunotherapy for osteosarcoma via a pH-responsive multi-component nanoparticle system

Synergistic chemo-immunotherapy for osteosarcoma via a pH-responsive multi-component nanoparticle system

IntroductionOsteosarcoma (OS) is the most common primary malignant bone tumor in pediatric populations. Its treatment is complicated by chemotherapy-induced toxicity and limited induction of immunogenic cell death (ICD).MethodsTo address these challenges, we developed a pH-responsive, multi-componen...

Full description

Saved in:

Bibliographic Details
Main Authors:	Dapeng Li, Yuanfan Li, Jie Cang, Xianwen Yan, Feipeng Wu, Xuan Sun, Wenchao Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-04-01
Series:	Frontiers in Pharmacology
Subjects:	osteosarcoma pH-responsive immune-modulating nanoparticles tumor microenvironment reprogramming immunogenic cell death TLR4 and STING agonists
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1584245/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy
by: Laura Gehrcken, et al.
Published: (2025-05-01)

Editorial: Therapeutic mechanism of osteosarcoma
by: Siyi Chen, et al.
Published: (2025-04-01)

New insights into the mechanisms of the immune microenvironment and immunotherapy in osteosarcoma
by: Cong Luo, et al.
Published: (2025-01-01)

Potential therapeutic strategies for colitis and colon cancer: bidirectional targeting STING pathway
by: Jiaorong Qu, et al.
Published: (2025-01-01)

Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics
by: BingBing Li, et al.
Published: (2025-02-01)

Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy
by: Xiaoyan Qi, et al.
Published: (2024-12-01)

Lipid metabolic reprogramming and associated ferroptosis in osteosarcoma: From molecular mechanisms to potential targets
by: Zhiyang Yin, et al.
Published: (2025-04-01)

PD-L1-targeted polymer-peptide-immune nanomedicine synergizes radiotherapy for durable tumor control
by: Jincheng Du, et al.
Published: (2025-09-01)

Progress Update on STING Agonists as Vaccine Adjuvants
by: Yanru Shen, et al.
Published: (2025-03-01)

Adjunctive beneficial effect of c-di-GMP, a STING agonist, in enhancing protective efficacy of TLR4-adjuvanted tuberculosis subunit vaccine formulations
by: Kee Woong Kwon, et al.
Published: (2025-05-01)

A Novel Application Paradigm for Tumor In-Situ Vaccination: Synergistic Effects of TLR7/8 Agonists and Radiotherapy
by: Xiaolin YOU, et al.
Published: (2025-07-01)

Scutellarein Inhibits Osteosarcoma Growth by Targeting the TLR4/TRAF6/NF-κB Pathway
by: Shi Y, et al.
Published: (2025-01-01)

Immunogenic Cell Death and Metabolic Reprogramming in Cancer: Mechanisms, Synergies, and Innovative Therapeutic Strategies
by: Jie Jiang, et al.
Published: (2025-04-01)

Near-infrared photoimmunotherapy for osteosarcoma targeting epidermal growth factor receptor
by: Motofumi Suzuki, et al.
Published: (2024-12-01)

Single‐Cell RNA Sequencing Reveals the Critical Role of SEC16B in Lung Metastasis of Osteosarcoma
by: Shangyu Liu, et al.
Published: (2025-08-01)

TRDMT1 methyltransferase gene knockout attenuates STING-based cell death signaling during self-extracellular RNA-mediated response in drug-induced senescent osteosarcoma cells
by: Gabriela Betlej, et al.
Published: (2025-08-01)

GTSE1-expressed osteoblastic cells facilitate formation of pro-metastatic tumor microenvironment in osteosarcoma
by: Linzhu Wang, et al.
Published: (2025-11-01)

Leveraging diverse cell death patterns in osteosarcoma patients and identification of the function of FADS2 in osteosarcoma cells
by: Guannan Bai, et al.
Published: (2025-07-01)

Targeting Metabolic Reprogramming in Bladder Cancer Immunotherapy: A Precision Medicine Approach
by: Fuyang Liu, et al.
Published: (2025-05-01)

Multi-omics analysis of copper metabolism-related molecular subtypes and risk stratification for osteosarcoma
by: Yang Zhang, et al.
Published: (2025-04-01)

Constructing a prognostic model for osteosarcoma based on centrosome-related genes and identifying potential therapeutic targets of paclitaxel
by: Yujian Zhong, et al.
Published: (2025-05-01)

Exploration of metastasis-related signatures in osteosarcoma based on tumor microenvironment by integrated bioinformatic analysis
by: Shiyao Liao, et al.
Published: (2025-01-01)

Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights
by: Yi Zhang, et al.
Published: (2025-06-01)

Tumor microenvironment in osteosarcoma: From cellular mechanism to clinical therapy
by: Yihan Yu, et al.
Published: (2025-09-01)

A telomere-related signature for predicting prognosis and assessing immune microenvironment in osteosarcoma
by: Shihao Li, et al.
Published: (2025-01-01)

Multidisciplinary approach to the accurate diagnosis of parosteal osteosarcoma
by: Miroslav Kilian, et al.
Published: (2025-07-01)

Corrigendum: A telomere-related signature for predicting prognosis and assessing immune microenvironment in osteosarcoma
by: Shihao Li, et al.
Published: (2025-06-01)

Dual regulation of the cGAS-STING pathway: new targets and challenges for subtype-specific immunotherapy in breast cancer
by: Hanchu Xiong, et al.
Published: (2025-06-01)

Identification of telomere-related gene subtypes and prognostic signatures in osteosarcoma
by: Zhaoguang Song, et al.
Published: (2025-02-01)

A Purely Biomanufactured System for Delivering Nanoparticles and STING Agonists
by: Yu‐an Li, et al.
Published: (2025-01-01)

Based on single-cell and transcriptome data, ferroptosis and the immunological landscape in osteosarcoma were discovered
by: Yingcun Jiang, et al.
Published: (2025-04-01)

PROSPECTS OF Toll-LIKE RECEPTOR AGONISTS AND ANTAGONISTS FOR PREVENTION AND TREATMENT OF VIRAL INFECTIONS
by: A. A. Nikonova, et al.
Published: (2019-07-01)

Conjugated STING agonists
by: Shuhao Qu, et al.
Published: (2025-06-01)

Screening and identification Hub genes associated with immune cell infiltration and critical biomarkers in osteosarcoma
by: Xin Song, et al.
Published: (2025-08-01)

The activation of cGAS-STING pathway offers novel therapeutic opportunities in cancers
by: Yumin Wang, et al.
Published: (2025-06-01)

The malignant dialogue between cancer-associated fibroblasts and osteosarcoma cells: microenvironment-mediated drug resistance and therapeutic targets
by: Xiufeng Wang, et al.
Published: (2025-08-01)

Photothermal therapy combined with a STING agonist induces pyroptosis, and gasdermin D could be a new biomarker for guiding the treatment of pancreatic cancer
by: Yanyan Hu, et al.
Published: (2025-03-01)

Commentary: Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives
by: Nan Zhang, et al.
Published: (2025-07-01)

A case of primary extraskeletal osteosarcoma of the breast
by: Kanako Kurata, et al.
Published: (2018-09-01)

The osteosarcoma immune microenvironment in progression: PLEK as a prognostic biomarker and therapeutic target
by: Yunpeng Zou, et al.
Published: (2025-08-01)